AURAVAX THERAPEUTICS, INC.
HOUSTON, TEXAS 770097431
$750K
Total Contract Value
3 awards
First Award
Sep 16, 2024
Last Award
Jun 3, 2025
Business Size
small
CAGE Code
969E2
Top Industries (NAICS)
| NAICS Code | Obligations | Awards |
|---|---|---|
| 541714 | $750K | 3 |
Contract Awards
1 awards found
75A50124C00054
Department of Health and Human Services
$750K
Sep 16, 2024
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN
NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2024
Business Details
- UEI
- PAN3ZK2YLAL2
- CAGE Code
- 969E2
- Address
- 807 WENDEL STREET
HOUSTON, TX 770097431 - Congressional District
- TX-18
- Phone
- 2674219792
Parent Company
AURAVAX THERAPEUTICS, INC.
Data Source
This profile is based on federal contract award data from USAspending.gov.
View on USAspending.gov